55I0 Stock Chart & Stats
€12.28
€0.85(6.27%)
At close: 4:00 PM EDT
€12.28
€0.85(6.27%)
Day’s Range― - ―
52-Week Range€12.12 - €26.40
Previous CloseN/A
Volume0.00
Average Volume (3M)20.00
Market Cap
€3.41B
Enterprise Value€5.79B
Total Cash (Recent Filing)€425.30M
Total Debt (Recent Filing)€1.23B
Price to Earnings (P/E)155.3
Beta0.62
Next Earnings
Oct 27, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding243,278,090
10 Day Avg. Volume10
30 Day Avg. Volume20
Financial Highlights & Ratios
PEG Ratio-1.05
Price to Book (P/B)2.89
Price to Sales (P/S)5.82
P/FCF Ratio50.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.95Price Target Upside70.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)0.49
Revenue Forecast (FY)€1.01B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationImproving operating and free cash flow gives Mirion greater capacity to fund product development, integration, debt reduction, and shareholder returns internally. This strengthens financial resilience and supports continued investment even while reported profitability remains relatively modest.
Backlog And Nuclear DemandA substantially expanded backlog improves forward revenue visibility and supports the durability of demand for Mirion’s specialized monitoring systems. Strong nuclear and SMR orders also align the company with long-cycle installed-base, life-extension, and digital-transformation spending.
Improved Balance SheetLower leverage and a sizable equity base provide more financial flexibility to absorb project timing variability and pursue strategic investments. The improved balance-sheet profile also reduces pressure on cash resources, supporting Mirion’s ability to manage its long-cycle customer programs.
Bears Say
Thin And Volatile ProfitabilityDespite returning to positive net income, Mirion’s low operating and net margins leave limited protection against cost increases, weaker demand, or execution setbacks. The history of losses indicates that improved earnings power is not yet fully established across the business cycle.
Weak Organic Medical GrowthSoft organic growth in medical and dosimetry reduces the quality and breadth of current expansion, increasing reliance on acquisitions and stronger nuclear demand. Persistent weakness could limit mix improvement and make the company’s overall growth trajectory more dependent on execution.
M&A Margin Dilution And Timing RiskIntegration-related dilution can delay the conversion of revenue growth into durable operating leverage, while project slippage can move backlog revenue between periods. Together, these factors make near-term margin improvement and backlog conversion less predictable despite strong demand.
55I0 FAQ
What was Mirion Technologies’s price range in the past 12 months?
Mirion Technologies lowest stock price was €12.12 and its highest was €26.40 in the past 12 months.
What is Mirion Technologies’s market cap?
Mirion Technologies’s market cap is €3.41B.
When is Mirion Technologies’s upcoming earnings report date?
Mirion Technologies’s upcoming earnings report date is Oct 27, 2026 which is in 5 days.
How were Mirion Technologies’s earnings last quarter?
Mirion Technologies released its earnings results on Jul 28, 2026. The company reported €0.107 earnings per share for the quarter, beating the consensus estimate of €0.092 by €0.015.
Is Mirion Technologies overvalued?
According to Wall Street analysts Mirion Technologies’s price is currently Undervalued.
Does Mirion Technologies pay dividends?
Mirion Technologies does not currently pay dividends.
What is Mirion Technologies’s EPS estimate?
Mirion Technologies’s EPS estimate is 0.11.
How many shares outstanding does Mirion Technologies have?
Mirion Technologies has 243,278,090 shares outstanding.
What happened to Mirion Technologies’s price movement after its last earnings report?
Mirion Technologies reported an EPS of €0.107 in its last earnings report, beating expectations of €0.092. Following the earnings report the stock price went up 4.156%.
Which hedge fund is a major shareholder of Mirion Technologies?
Currently, no hedge funds are holding shares in DE:55I0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mirion Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.95 (70.59% Upside)
€20.95 (70.59% Upside)
Blogger Sentiment
Bullish
DE:55I0 Sentiment 60%
Sector Average 63%
Sector Average 63%
Insider Transactions
Bought Shares
Worth €277.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.17%
12-Months-Change
Fundamentals
Return on Equity
1.33%
Trailing 12-Months
Asset Growth
28.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mirion Technologies
Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).
55I0 Company Deck
55I0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by substantial backlog and order growth (notably in nuclear power and SMRs), expanding adjusted EBITDA margins, robust free cash flow, successful integration of Paragon, and maintained full-year guidance with good revenue coverage. Offsetting risks include weak organic revenue (medical softness and dosimetry declines), an $18M China debooking, M&A-related margin dilution, and timing/execution risk on large opportunities. On balance the positive drivers (backlog growth, margin expansion, cash generation, large wins, AI/product innovation) materially outweigh the near-term challenges, supporting constructive outlook for the remainder of 2026.View all DE:55I0 earnings summaries55I0 Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€20.95
▲(70.59% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Babcock & Wilcox Company
―
Graham
―
Hadron Energy
―
X-Energy, Inc. Class A
―
Deep Fission
―







